Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Potent P2Y12 inhibitors like prasugrel and ticagrelor are crucial in managing acute coronary syndrome (ACS).
• A direct comparison of their long-term efficacy and safety in real-world clinical practice is limited.
• Understanding comparative outcomes is essential for optimizing antiplatelet therapy.

Purpose of the Study:

• To compare the efficacy and safety of prasugrel versus ticagrelor in ACS patients post-percutaneous coronary intervention.
• To evaluate a decade of clinical experience with these third-generation antiplatelet agents.
• To assess cardiovascular events and bleeding risk associated with each drug.

Main Methods:

• Retrospective observational study of 746 ACS patients from January 2010 to December 2019.
• Patients received aspirin plus either prasugrel or ticagrelor after percutaneous coronary intervention.
• Primary endpoint: composite of cardiovascular death, recurrent coronary syndrome, or ischemic stroke at one year. Secondary endpoint: significant bleeding (BARC types 3, 4, or 5).

Main Results:

• No significant difference in the primary endpoint between ticagrelor (8.0%) and prasugrel (10.3%) groups (p=0.303).
• Significant bleeding rates were similar: 2.9% for ticagrelor vs. 3% for prasugrel (p=0.9).
• Higher treatment discontinuation rates were observed with ticagrelor (16.7%) compared to prasugrel (9.6%) (p=0.003).

Conclusions:

• Prasugrel and ticagrelor demonstrate comparable efficacy and safety profiles regarding major adverse cardiac events and significant bleeding in ACS patients.
• Clinicians may consider treatment discontinuation rates when selecting between these potent P2Y12 inhibitors.
• Further prospective studies could validate these findings in diverse patient populations.